DALLAS, July 16, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Northwest Biotherapeutics Inc. (OTCBB:NWBO). The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.
Our trade alerts and ideas are provided free to investors. Simply use your email address to subscribe with http://www.microstockprofit.com to get the inside track on our next red-hot alert.
The full report is available at: http://www.microstockprofit.com/lp/NWBO
NWBO's recent volatility has been greater than normal. This is evidenced by the increased distance between the upper and lower Bollinger Bands. These bands measure volatility using standard deviation and a large width is due to high volatility.
Northwest Biotherapeutics Inc. (NWBO) is a development-stage biotechnology company focused on discovering, developing and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer. The Company's approach in developing cancer therapies utilizes its capability in the biology of dendritic cells (DC), which are a type of white blood cells that activate the immune system. It's focus is on advancing a dendritic cell immunotherapy for prostate and brain cancer. NWBO has two basic technology platforms applicable to cancer therapeutics: dendritic cell-based cancer vaccines, which it calls DCVax, and monoclonal antibodies for cancer therapeutics. Its DCVax dendritic cell-based cancer vaccine program is its main technology platform.
Message Board Search for NWBO: http://www.boardcentral.com/boards/NWBO
In the report, the analyst notes:
"The Company's approach in developing cancer therapies utilizes its expertise in the biology of dendritic cells, which are a type of white blood cell that activate the immune system ... the Company believes that DCVax may overcome certain limitations of current cancer therapies and offer cancer patients safe and effective treatment alternatives, alone or in combination with other therapies.
"BioMedReports.com recently issued a report featuring NWBO's DCVax immunotherapy vaccines to treat cancer. According to the report, NWBO's DCVax 'may be poised to surpass Dendreon's product in the field of vaccine based cancer treatments.' The article also focused on the 'hard differentiators' between NWBO's immunotherapy vaccine platform and that of its closest rival."
To read the entire report visit: http://www.microstockprofit.com/lp/NWBO
See what investors are saying about NWBO at penny stock forum
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.